Kurumi Hiroki, Yokoyama Yoshihiro, Hirano Takehiro, Akita Kotaro, Hayashi Yuki, Kazama Tomoe, Isomoto Hajime, Nakase Hiroshi
Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo 060-8543, Hokkaido, Japan.
Division of Gastroenterology and Nephrology, Department of Multidisciplinary Internal Medicine, Tottori University Faculty of Medicine, 36-1, Nishi-cho, Yonago 683-8504, Tottori, Japan.
Biomedicines. 2024 Apr 25;12(5):952. doi: 10.3390/biomedicines12050952.
Cytokine-targeted therapies have shown efficacy in treating patients with ulcerative colitis (UC), but responses to these advanced therapies can vary. This variability may be due to differences in cytokine profiles among patients with UC. While the etiology of UC is not fully understood, abnormalities of the cytokine profiles are deeply involved in its pathophysiology. Therefore, an approach focused on the cytokine profile of individual patients with UC is ideal. Recent studies have demonstrated that molecular analysis of cytokine profiles in UC can predict response to each advanced therapy. This narrative review summarizes the molecules involved in the efficacy of various advanced therapies for UC. Understanding these associations may be helpful in selecting optimal therapeutic agents.
细胞因子靶向疗法已显示出治疗溃疡性结肠炎（UC）患者的疗效，但对这些先进疗法的反应可能会有所不同。这种变异性可能是由于UC患者细胞因子谱的差异。虽然UC的病因尚未完全了解，但细胞因子谱的异常在其病理生理学中密切相关。因此，针对UC个体患者细胞因子谱的方法是理想的。最近的研究表明，UC中细胞因子谱的分子分析可以预测对每种先进疗法的反应。这篇叙述性综述总结了参与各种UC先进疗法疗效的分子。了解这些关联可能有助于选择最佳治疗药物。
